AQR's four-series filing reports $145.6M sold, no stated ceiling

AQR filed four Form Ds on September 24 covering four series of AQR Flex 1 Series LLC, and together they report $145.6 million already sold to investors, all with the same date of first sale, September 9. The money had been in the door a full fifteen days before the paperwork caught up.

Series D16 alone accounts for $90 million of the total, with F72 at $25 million, F73 at $15.6 million and A93 at $15 million, a distribution that parks roughly 62% of the batch in a single sleeve. Each filing lists the fund type as hedge fund and the industry group as pooled investment fund, and none of the four states a total offering amount, which leaves the sold-to-date column as the only size the documents give.

Every series files as its own issuer, with its own investors and its own sold figure, under one name; the related-persons line names the same pair on all four, AQR Capital Management, LLC and AQR Capital Management II, LLC.

The structure carries more information than the dollar figures: one name, AQR Flex 1 Series LLC, sits above four issuers that file separately, each with its own sold figure, which suggests a shelf being loaded rather than four independent launches. None of the four filings describes a strategy, a capacity or a fee, so the reasons stay with the manager rather than the record.

The designations point the same way, with A93, D16, F72 and F73 sitting deep into their letter sequences, the mark of a shelf that gets reloaded.

This publication has argued that the pricing unit in alternatives distribution has moved to the wrapper, not the fund, and the Flex filings show that migration arriving on the hedge-fund side of the business, where four cells file under one name and money comes in sleeve by sleeve. The likely appeal for the manager is that a sleeve can hold a mandate that would otherwise live in a separate account, with the strategy, the fee and the investor list all inside the firm's own vehicle.

For the advisor or platform gatekeeper doing diligence, that leaves no AQR Flex 1 fund to size, only cells—and one of them holds $90 million, a sleeve that could be a single institutional mandate and that the public record describes no further.

Cells that keep adding sold figures are a subscription pipeline; cells that stay flat at their first reported totals are likely one mandate each. From outside, the wrapper makes the two look the same, so watch the amendments.